Form 4: Aspira Women's Health Director Celeste Rachelle Fralick Reports Stock Conversion
SEC Form 4
Director Celeste Rachelle Fralick reports the conversion of restricted stock units into common stock of Aspira Women's Health Inc.
Summary
- On March 31, 2025, Celeste Rachelle Fralick, a director of Aspira Women's Health Inc., converted 5,000 restricted stock units (RSUs) into common stock.
- This transaction was reported on a Form 4 filed with the SEC on April 1, 2025.
- Following the transaction, Fralick directly owns 5,000 derivative securities and 55,665 shares of common stock.
Sentiment
Score: 5
Explanation: This is a neutral event, reflecting scheduled vesting of compensation.
Industry Context
This is a routine disclosure related to insider transactions and is a standard part of corporate governance.
Stakeholder Impact
- The conversion of RSUs into common stock may have a minor dilutive effect on existing shareholders.
Key Dates
| Date | Description |
|---|---|
| 08/22/2024 | Reporting person was granted 20,000 RSUs. |
| 08/26/2024 | RSUs were previously reported in Table II on a Form 4 filed with the SEC. |
| 03/31/2025 | 5,000 RSUs vested and were converted into common stock. |
| 04/01/2025 | Form 4 filing date. |
Keywords
Form 4, insider trading, Celeste Rachelle Fralick, Aspira Women's Health Inc., stock conversion, restricted stock units, AWH, director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.